Ionic liquid-promoted one-pot synthesis of thiazole-imidazo[2,1-b][1,3,4]thiadiazole hybrids and their antitubercular activity

dc.contributor.authorRamprasad, J.
dc.contributor.authorNayak, N.
dc.contributor.authorUdayakumar, D.
dc.contributor.authorYogeeswari, P.
dc.contributor.authorSriram, D.
dc.date.accessioned2026-02-05T09:33:17Z
dc.date.issued2016
dc.description.abstractIn this paper, we report the facile and efficient one-pot three-component synthesis of 1-((6-phenylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)-2-(4-phenylthiazol-2-yl)hydrazine derivatives (5a-w) using an ionic liquid, namely 1-butyl-3-methylimidazolium bromide ([Bmim]Br). The compounds were screened for their in vitro antimycobacterial activity against Mycobacterium tuberculosis. Compound 5s showed the highest inhibitory activity with an MIC of 6.03 ?M which is slightly lower than the MIC values of standard drugs ethambutol (15.3 ?M) and ciprofloxacin (9.4 ?M). Four other compounds of the series viz.5e, 5i, 5t and 5w also showed significant inhibitory activity with MIC values in the range of 11.7-13.9 ?M. The structure-activity relationship revealed that the trifluoromethyl substitution at position-2 and p-chlorophenyl substitution at position-6 of the imidazo[2,1-b][1,3,4]thiadiazole ring enhanced the inhibitory activity. Also, the methyl, methoxy, fluoro or nitro substituents on the thiazole ring enhanced the activity of the compounds. None of the active compounds were toxic to a normal cell line (NIH 3T3), which signifies the lack of general cellular toxicity of the molecules. In silico molecular docking studies revealed the favourable interaction of the potent compounds with the target enzymes InhA and CYP121. © The Royal Society of Chemistry 2016.
dc.identifier.citationMedChemComm, 2016, 7, 2, pp. 338-344
dc.identifier.issn20402503
dc.identifier.urihttps://doi.org/10.1039/c5md00346f
dc.identifier.urihttps://idr.nitk.ac.in/handle/123456789/26064
dc.publisherRoyal Society of Chemistry
dc.subject1 butyl 3 methylimidazolium bromide
dc.subject1 [(6 phenylimidazo[2,1 b][1,3,4]thiadiazol 5 yl)methylene] 2 (4 phenylthiazol 2yl)hydrazine derivative
dc.subject1 [[6 (4 chlorophenyl) 2 (trifluoromethyl)imidazo[2,1 b][1,3,4]thiadiazol 5 yl]methylene] 2 (4 p tolylthiazol 2 yl)hydrazine
dc.subjectciprofloxacin
dc.subjectcytochrome P450
dc.subjectcytochrome P450 121
dc.subjectethambutol
dc.subjectInhA protein
dc.subjectionic liquid
dc.subjectisoniazid
dc.subjectoxidoreductase
dc.subjecttuberculostatic agent
dc.subjectunclassified drug
dc.subject3T3 cell line
dc.subjectanimal cell
dc.subjectantibacterial activity
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdrug screening
dc.subjectdrug synthesis
dc.subjectEscherichia coli
dc.subjectin vitro study
dc.subjectminimum inhibitory concentration
dc.subjectmolecular docking
dc.subjectmouse
dc.subjectMycobacterium tuberculosis
dc.subjectnonhuman
dc.subjectone pot synthesis
dc.subjectpriority journal
dc.subjectPseudomonas aeruginosa
dc.subjectStaphylococcus aureus
dc.subjectstructure activity relation
dc.titleIonic liquid-promoted one-pot synthesis of thiazole-imidazo[2,1-b][1,3,4]thiadiazole hybrids and their antitubercular activity

Files

Collections